Literature DB >> 1729263

Mitotic indexes as prognostic predictors in female breast cancer.

S Aaltomaa1, P Lipponen, M Eskelinen, V M Kosma, S Marin, E Alhava, K Syrjänen.   

Abstract

A series of 688 women with breast cancer were followed-up for a mean of 13 years. Tumour size, axillary lymph node status, histological grade, histological type and two mitotic indexes (M/V; MAI) were assessed and related to disease outcome. Primary tumour size (P less than 0.0001), the volume-corrected mitotic index (M/V) (P less than 0.0001), the mitotic activity index (MAI) (P = 0.0001), and histological grade (P = 0.0074) predicted axillary lymph node status. Recurrence as well as recurrence-free survival was significantly related to the axillary lymph node status (P less than 0.0001), M/V index (P less than 0.0001), MAI (P less than 0.0001), tumour size (P = 0.0031) and histological grade (P = 0.0208). Multivariate analyses disclosed the tumour size and M/V index as independent predictors of axillary metastasis at diagnosis. Recurrence was related independently to M/V index, axillary metastasis and tumour size. Independent predictors of recurrence-free survival in Cox's analysis were M/V index and axillary lymph node status. Axillary lymph node status (P less than 0.0001), tumour size (P less than 0.0001), M/V index (P less than 0.0001), MAI (P less than 0.0001) and histological grade (P = 0.0009) predicted survival in that order. Cox's analysis showed that axillary lymph node status was the most important independent predictor of survival followed by tumour size and M/V index. In a separate Cox's analysis of axillary-lymph-node-negative patients the M/V index and tumour size were independently related to survival. In conclusion the M/V index is an important prognostic factor in breast cancer and also in axillary-lymph-node-negative breast tumours.

Entities:  

Mesh:

Year:  1992        PMID: 1729263     DOI: 10.1007/bf01192316

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  An improved prognostic index of axillary node involvement in breast cancer incorporating DNA ploidy and tumour size.

Authors:  M Eskelinen; Y Collan; P Pajarinen; E Pesonen; K Kettunen; S Nordling
Journal:  Acta Chir Scand       Date:  1990-08

2.  Relationship between DNA flow cytometric data, nuclear morphometric variables and volume-corrected mitotic index in transitional cell bladder tumors.

Authors:  P K Lipponen; M J Eskelinen; S Nordling
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

3.  Sampling in diagnostic morphometry: the influence of variation sources.

Authors:  Y Collan; T Torkkeli; V M Kosma; E Pesonen; O Kosunen; E Jantunen; G M Mariuzzi; R Montironi; F Marinelli; G Collina
Journal:  Pathol Res Pract       Date:  1987-06       Impact factor: 3.250

4.  Prognostic significance of the Ackerman classification and other histopathological characteristics in breast cancer. An analysis of 1,349 consecutive cases with complete follow-up over seven years.

Authors:  L Holmberg; H O Adami; A Lindgren; A Ekbom; A Sandström; R Bergström
Journal:  APMIS       Date:  1988-11       Impact factor: 3.205

5.  How to count mitoses in bladder cancer grading?

Authors:  P K Lipponen; M J Eskelinen
Journal:  Anticancer Res       Date:  1991 Mar-Apr       Impact factor: 2.480

6.  Prediction of superficial bladder cancer by histoquantitative methods.

Authors:  P K Lipponen; M J Eskelinen; M Sotarauta
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

7.  Volume-corrected mitotic index in human pancreatic cancer. Relation to histologic grade, clinical stage, and prognosis.

Authors:  P K Lipponen; M J Eskelinen; Y Collan; S Marin; E Alhava
Journal:  Scand J Gastroenterol       Date:  1990-06       Impact factor: 2.423

8.  Potential of nuclear morphometry and volume-corrected mitotic index in grading transitional cell carcinoma of the urinary bladder.

Authors:  P K Lipponen; V M Kosma; Y Collan; T Kulju; O Kosunen; M Eskelinen
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

9.  Prognostic factors in human pancreatic cancer, with special reference to quantitative histology.

Authors:  M Eskelinen; P Lipponen; S Marin; H Haapasalo; K Mäkinen; H Ahtola; J Puittinen; P Nuutinen; E Alhava
Journal:  Scand J Gastroenterol       Date:  1991-05       Impact factor: 2.423

10.  Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms.

Authors:  H Haapasalo; E Pesonen; Y Collan
Journal:  Pathol Res Pract       Date:  1989-11       Impact factor: 3.250

View more
  8 in total

Review 1.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer.

Authors:  T Pietiläinen; P Lipponen; S Aaltomaa; M Eskelinen; V M Kosma; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 3.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

4.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

5.  Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration.

Authors:  L P Setälä; V M Kosma; S Marin; P K Lipponen; M J Eskelinen; K J Syrjänen; E M Alhava
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

Review 6.  Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?

Authors:  Umar Wazir; Kinan Mokbel; Amtul Carmichael; Kefah Mokbel
Journal:  Cell Mol Biol Lett       Date:  2017-09-04       Impact factor: 5.787

7.  Proliferative activity in Libyan breast cancer with comparison to European and Central African patients.

Authors:  Jamela Boder; Fathi Abdalla; Mohamed Elfagieh; Abdelbaset Buhmeida; Yrjö Collan
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

8.  Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?

Authors:  David Oddó; Dahiana Pulgar; Nicole Elgueta; Francisco Acevedo; Dravna Razmiliz; María Elena Navarro; Mauricio Camus; Tomás Merino; Ignacio Retamal; Alejandra Pérez-Sepúlveda; Alejandra Villarroel; Héctor Galindo; José Peña; César Sánchez
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.